Literature DB >> 12811638

[3H]GR113808 binding to serotonin 5-HT(4) receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study.

M K Lai1, S W Tsang, P T Francis, M M Esiri, T Hope, O F Lai, I Spence, C P Chen.   

Abstract

Abnormalities in neural transmission of serotonin (5-HT) may play a role in both cognitive and neuropsychiatric features of Alzheimer disease (AD). We measured 5-HT(4) receptors in the postmortem frontal and temporal cortex of 34 AD subjects and 15 controls by radioligand binding with [3H]GR113808. Receptor binding data was then correlated with prospectively assessed cognitive (Mini-Mental State Examination, MMSE) and behavioral (Present Behavioural Examination, PBE) data. [3H]GR113808 binding affinity (K(D)) and density (B(max)) in AD were unchanged compared to controls in both cortical regions, and did not correlate with MMSE or PBE data. The binding parameters were also not related to disease duration, senile plaque and neurofibrillary tangle counts, and neuroleptic medication. We conclude that unlike other 5-HT receptors, 5-HT(4) receptor binding affinity and density do not seem to be affected in the frontal and temporal cortex in AD and may not have a direct role in the clinical features of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811638     DOI: 10.1007/s00702-003-0825-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  9 in total

1.  Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study.

Authors:  Karine Madsen; Mette T Haahr; Lisbeth Marner; Sune H Keller; William F Baaré; Claus Svarer; Steen G Hasselbalch; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2011-03-02       Impact factor: 6.200

Review 2.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 3.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 4.  Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Authors:  Dag Aarsland; Sally Sharp; Clive Ballard
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 5.  A pharmacological analysis of an associative learning task: 5-HT(1) to 5-HT(7) receptor subtypes function on a pavlovian/instrumental autoshaped memory.

Authors:  Alfredo Meneses
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

Review 6.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

Review 7.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

Review 8.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

Review 9.  Alterations of Expression of the Serotonin 5-HT4 Receptor in Brain Disorders.

Authors:  Heike Rebholz; Eitan Friedman; Julia Castello
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.